TGA provisionally approves Novavax (Biocelect Pty Ltd's) COVID-19 vaccine NUVAXOVID
On 19 January 2022 the TGA granted provisional approval to Biocelect Pty Ltd (on behalf of Novavax Inc) in relation to the COVID-19 vaccine, NVX-CoV2373, for individuals aged 18 years and over.
Published
Related content
-
TGA provisionally approves the Biocelect Pty Ltd (Novavax) COVID-19 vaccine, NUVAXOVID, for use in individuals aged 12-17 years
The TGA has provisionally approved the Biocelect Pty Ltd (on behalf of Novavax Inc.) COVID-19 vaccine, NUVAXOVID, for use in individuals aged 12 years and older. -
TGA provisionally approves Moderna's COVID-19 vaccine
On 9 August 2021 the TGA granted provisional approval to Moderna Australia Pty Ltd in relation to the COVID-19 vaccine, Spikevax (elasomeran), for individuals aged 18 years and over. -
TGA provisionally approves Moderna’s COVID-19 vaccine for use as a booster dose in individuals 12 years and older
On 19 October 2022, the TGA provisionally approved Moderna's COVID-19 vaccine, SPIKEVAX (elasomeran), for use as a booster dose in individuals aged 12 years and older.